• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Lkb1 失活驱动由 Polycomb 抑制复合物 2 调控的肺癌谱系转换。

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

出版信息

Nat Commun. 2017 Apr 7;8:14922. doi: 10.1038/ncomms14922.

DOI:10.1038/ncomms14922
PMID:
28387316
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5385585/
Abstract

Adenosquamous lung tumours, which are extremely poor prognosis, may result from cellular plasticity. Here, we demonstrate lineage switching of KRAS+ lung adenocarcinomas (ADC) to squamous cell carcinoma (SCC) through deletion of Lkb1 (Stk11) in autochthonous and transplant models. Chromatin analysis reveals loss of H3K27me3 and gain of H3K27ac and H3K4me3 at squamous lineage genes, including Sox2, ΔNp63 and Ngfr. SCC lesions have higher levels of the H3K27 methyltransferase EZH2 than the ADC lesions, but there is a clear lack of the essential Polycomb Repressive Complex 2 (PRC2) subunit EED in the SCC lesions. The pattern of high EZH2, but low H3K27me3 mark, is also prevalent in human lung SCC and SCC regions within ADSCC tumours. Using FACS-isolated populations, we demonstrate that bronchioalveolar stem cells and club cells are the likely cells-of-origin for SCC transitioned tumours. These findings shed light on the epigenetics and cellular origins of lineage-specific lung tumours.

摘要

腺鳞肺癌预后极差,可能源于细胞可塑性。在这里,我们通过在自发和移植模型中敲除 Lkb1(Stk11),证实了 KRAS+肺腺癌(ADC)向鳞状细胞癌(SCC)的谱系转换。染色质分析显示,在包括 Sox2、ΔNp63 和 Ngfr 在内的鳞状谱系基因中,H3K27me3 的丢失和 H3K27ac 和 H3K4me3 的获得。与 ADC 病变相比,SCC 病变中 H3K27 甲基转移酶 EZH2 的水平更高,但 SCC 病变中明显缺乏必需的多梳抑制复合物 2(PRC2)亚基 EED。在人类肺 SCC 和 ADSCC 肿瘤中的 SCC 区域中,也存在高 EZH2 但 H3K27me3 标记明显缺乏的模式。通过 FACS 分离的细胞群,我们证明了支气管肺泡干细胞和 club 细胞是 SCC 转化肿瘤的可能起源细胞。这些发现揭示了谱系特异性肺癌的表观遗传学和细胞起源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/5a285d86c058/ncomms14922-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/4582fe40b4f2/ncomms14922-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/7d4095d36783/ncomms14922-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/d9e4b6949f9c/ncomms14922-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/f4d28f5bc584/ncomms14922-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/9f8e780486c5/ncomms14922-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/afa4aaa8ee4a/ncomms14922-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/5a285d86c058/ncomms14922-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/4582fe40b4f2/ncomms14922-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/7d4095d36783/ncomms14922-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/d9e4b6949f9c/ncomms14922-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/f4d28f5bc584/ncomms14922-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/9f8e780486c5/ncomms14922-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/afa4aaa8ee4a/ncomms14922-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f9e/5385585/5a285d86c058/ncomms14922-f7.jpg

相似文献

1
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.Lkb1 失活驱动由 Polycomb 抑制复合物 2 调控的肺癌谱系转换。
Nat Commun. 2017 Apr 7;8:14922. doi: 10.1038/ncomms14922.
2
Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.Ezh2在Kras驱动的肺腺癌中发挥肿瘤抑制作用。
Int J Biol Sci. 2017 May 16;13(5):652-659. doi: 10.7150/ijbs.19108. eCollection 2017.
3
Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors.多梳蛋白缺失驱动 FOXP2 高表达的侵袭性状态,可被表观遗传抑制剂靶向治疗。
Nat Commun. 2023 Jan 20;14(1):336. doi: 10.1038/s41467-023-35784-x.
4
Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation.在头颈部鳞状细胞癌中,抑制性 H3K27 三甲基化标记的失调导致鳞状分化失调。
Clin Cancer Res. 2013 Jan 15;19(2):428-41. doi: 10.1158/1078-0432.CCR-12-2505. Epub 2012 Nov 27.
5
EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.EZH2 变体在组蛋白甲基化和细胞分化中差异调节多梳抑制复合物 2。
Epigenetics Chromatin. 2018 Dec 6;11(1):71. doi: 10.1186/s13072-018-0242-9.
6
Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.多梳抑制复合物 2 蛋白 EZH1 和 EZH2 通过抑制具有常染色质启动子的基因来调节小鼠出生后肝细胞成熟和纤维化的时间。
Gastroenterology. 2019 May;156(6):1834-1848. doi: 10.1053/j.gastro.2019.01.041. Epub 2019 Jan 25.
7
Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.多梳抑制复合物 2 是 KRAS 驱动的非小细胞肺癌炎症和上皮-间充质转化的障碍。
Cancer Cell. 2016 Jan 11;29(1):17-31. doi: 10.1016/j.ccell.2015.12.006.
8
Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma.Lkb1基因缺陷小鼠的肺腺癌向鳞状细胞癌的转分化
Nat Commun. 2014;5:3261. doi: 10.1038/ncomms4261.
9
Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance.多梳抑制复合物2(PRC2)通路在癌细胞可塑性和耐药性中的作用。
Funct Integr Genomics. 2025 Mar 6;25(1):53. doi: 10.1007/s10142-025-01563-8.
10
EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.EZH2 蛋白表达与非小细胞肺癌的早期发病机制、肿瘤进展和预后相关。
Clin Cancer Res. 2013 Dec 1;19(23):6556-65. doi: 10.1158/1078-0432.CCR-12-3946. Epub 2013 Oct 4.

引用本文的文献

1
Histologic Transformation in Cancer: The Path for Clinical Translation.癌症中的组织学转化:临床转化之路。
Cancer Discov. 2025 Sep 4;15(9):1783-1793. doi: 10.1158/2159-8290.CD-24-1866.
2
Persistent lineage plasticity driving lung cancer development and progression.持续的谱系可塑性驱动肺癌的发生和发展。
Clin Transl Med. 2025 Aug;15(8):e70458. doi: 10.1002/ctm2.70458.
3
Involvement of KEAP1/NRF2 pathway in non-BRAF mutated squamous cell carcinoma of the thyroid.KEAP1/NRF2通路在非BRAF突变型甲状腺鳞状细胞癌中的作用

本文引用的文献

1
Squamous Transition of Lung Adenocarcinoma and Drug Resistance.肺腺癌的鳞状化生与耐药性
Trends Cancer. 2016 Sep;2(9):463-466. doi: 10.1016/j.trecan.2016.08.002. Epub 2016 Sep 2.
2
Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1.起源细胞将组织学类型谱与由突变型Kras和Lkb1缺失驱动的非小细胞肺癌中的免疫微环境多样性联系起来。
Cell Rep. 2017 Jan 17;18(3):673-684. doi: 10.1016/j.celrep.2016.12.059.
3
Rare SOX2 Airway Progenitor Cells Generate KRT5 Cells that Repopulate Damaged Alveolar Parenchyma following Influenza Virus Infection.
J Pathol. 2025 Aug;266(4-5):481-494. doi: 10.1002/path.6444. Epub 2025 Jul 2.
4
Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation.揭示肺腺鳞癌转化中的免疫机制和治疗靶点。
Front Immunol. 2025 Jun 3;16:1542526. doi: 10.3389/fimmu.2025.1542526. eCollection 2025.
5
Tumor suppressors in Sox2-mediated lung cancers promote distinct cell-intrinsic and immunologic remodeling.Sox2介导的肺癌中的肿瘤抑制因子促进不同的细胞内在和免疫重塑。
JCI Insight. 2025 May 6;10(12). doi: 10.1172/jci.insight.171364. eCollection 2025 Jun 23.
6
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers.LKB1调节KRAS突变型肺癌中依赖JNK的应激信号传导和凋亡依赖性。
Nat Commun. 2025 May 2;16(1):4112. doi: 10.1038/s41467-025-58753-y.
7
KLF4 promotes a KRT13+ hillock-like state in squamous lung cancer.KLF4在肺鳞癌中促进形成KRT13+小丘样状态。
bioRxiv. 2025 Mar 13:2025.03.10.641898. doi: 10.1101/2025.03.10.641898.
8
Glycogen drives tumour initiation and progression in lung adenocarcinoma.糖原驱动肺腺癌的肿瘤起始和进展。
Nat Metab. 2025 Mar 11. doi: 10.1038/s42255-025-01243-8.
9
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy.上呼吸道和上消化道鳞状细胞癌:生物学、遗传学与治疗的统一视角
Cancer Cell. 2025 Feb 10;43(2):178-194. doi: 10.1016/j.ccell.2025.01.003.
10
Organoid modeling reveals the tumorigenic potential of the alveolar progenitor cell state.类器官建模揭示了肺泡祖细胞状态的致瘤潜力。
EMBO J. 2025 Mar;44(6):1804-1828. doi: 10.1038/s44318-025-00376-6. Epub 2025 Feb 10.
罕见的SOX2气道祖细胞可产生KRT5细胞,这些细胞在流感病毒感染后可重新填充受损的肺泡实质。
Stem Cell Reports. 2016 Nov 8;7(5):817-825. doi: 10.1016/j.stemcr.2016.09.010. Epub 2016 Oct 20.
4
SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin.SOX2是促进不同起源细胞发生肺鳞状细胞癌的决定性致癌开关。
Cancer Cell. 2016 Oct 10;30(4):519-532. doi: 10.1016/j.ccell.2016.09.001.
5
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.EZH2的致癌性失调作为肺癌靶向治疗的契机
Cancer Discov. 2016 Sep;6(9):1006-21. doi: 10.1158/2159-8290.CD-16-0164. Epub 2016 Jun 16.
6
Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.使用聚合酶链反应(PCR)结合下一代测序和桑格测序方法筛查肺腺鳞癌中的主要驱动癌基因改变。
Sci Rep. 2016 Feb 29;6:22297. doi: 10.1038/srep22297.
7
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.STK11/LKB1 缺陷促进中性粒细胞募集和促炎细胞因子产生,以抑制肺肿瘤微环境中的 T 细胞活性。
Cancer Res. 2016 Mar 1;76(5):999-1008. doi: 10.1158/0008-5472.CAN-15-1439. Epub 2016 Feb 1.
8
Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.多梳抑制复合物 2 是 KRAS 驱动的非小细胞肺癌炎症和上皮-间充质转化的障碍。
Cancer Cell. 2016 Jan 11;29(1):17-31. doi: 10.1016/j.ccell.2015.12.006.
9
Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma.肺腺鳞癌患者的临床病理特征及预后
J Huazhong Univ Sci Technolog Med Sci. 2015 Jun;35(3):350-355. doi: 10.1007/s11596-015-1436-z. Epub 2015 Jun 14.
10
Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?肺腺鳞癌的分子特征分析:混合型还是真正类型?
Oncotarget. 2015 Sep 15;6(27):23905-16. doi: 10.18632/oncotarget.4163.